Relevant Research Publications

The Impact of 10 years of human papillomavirus (HPV) vaccination in Australia

Cyra Patel, Julia ML Brotherton, Alexis Pillsbury, Sanjay Jayasinghe, Basil Donovan, Kristine Macartney, Helen Marshall

The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?

Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women

Suzanne M Garland, Alyssa M. Cornall, Julia M. L. Brotherton, John D. Wark, Michael J. Malloy, Sepehr N. Tabrizi on behalf of the VACCINE study group

Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program

Human papillomavirus vaccination update: nonavalent vaccine and the two-dose schedule

Brotherton JML.

Australian Journal of General Practice - 2018;47(7):417-421

The projected timeframe until cervical cancer elimination in Australia: a modelling study

Hall MT, Simms KT, Lew JB, Smith MA, Brotherton JML, Saville M, Frazer I, Canfell K

Lancet Public Health 2018. Published Online October 2, 2018

Very low prevalence of vaccine human papillomavirus (HPV) types among 18 to 35 year old Australian women, nine years following implementation of vaccination

Machalek DA, Garland SM, Brotherton JML, Bateson D, McNamee K, Stewart M, Skinner SR, Liu B, Cornall AM, Kaldor JM, Tabrizi SN

Journal of Infectious Diseases - 2018;217(10):1590-1600

Population level herd protection of males from a female human papillomavirus vaccination program: evidence from Australian serosurveillance

Pillsbury A, Quinn H, Hueston L, Evans T, McIntyre P, Brotherton JML

Clin Infect Dis - 2017;65(5):827-832

Progress in HPV vaccination in low and lower-middle income countries

LaMontagne DS, Bloem PJN, Brotherton JML, Gallagher KE, Ndiaye C, Badiane O

Int J Gynecol Obstet - 2017;138(Suppl 1.):7-14

HPV vaccination of immunocompromised hosts

Garland SM, Brotherton JML, Moscicki AB, Kaufmann AM, Stanley M, Bhatla N, Sankaranarayanan R, de Sanjose S, Palefsky JM

Papillomavirus Research 2017;4:35-38

Looking beyond human papillomavirus (HPV) genotype 16 and 18: defining HPV genotype distribution in cervical cancers in Australia prior to vaccination

Brotherton JML, Tabrizi SN, Phillips S, Pyman J, Cornall A, Lambie N, Anderson L, Cummings M, Payton D, Scurry JP, Newman M, Sharma R, Saville M, Garland S

Int J Cancer - 2017 Oct 15;141(8):1576-1584

Confirming cross-protection of bivalent HPV vaccine

Brotherton JML

Lancet Infect Dis. Published Online September 28, 2017

The impact of human papillomavirus catch-up vaccination in Australia: Implications for introduction of multiple age cohort vaccination and post-vaccination data interpretation

Drolet M, Laprise J-F, Brotherton JML, Donovan B, Fairley CK, Ali H, Benard E, Martin D, Brisson M

Journal of Infectious Diseases. 2017;10:1205-1209

A prospective study of the incidence of juvenile onset recurrent respiratory papillomatosis after implementation of a National HPV Vaccination Program

Novakovic D, Cheng ATL, Zurynski Y, Booy R, Walker PJ, Berkowitz R, Harrison H, Black R, Perry C, Vijayasekaran S, Wabnitz D, Burns H, Tabrizi SN, Garland SM, Elliott E, Brotherton JML

J Infect Dis - 2018 Jan 4;217(2):208-212

Safety of human papillomavirus vaccines: An updated review

Phillips A, Patel C, Pillsbury A, Brotherton JML, Macartney K

Drug Saf 2017;41(4):329-346

IPVS Statement Moving towards Elimination of Cervical Cancer as a Public Health Problem

Garland SM, Giuliano A, Brotherton JML, Moscicki AB, Stanley M, Kaufmann AM, Bhatla N, Sankaranarayanan R, Palefsky JM, de Sanjose S

Papillomavirus Research 2018;5:87-8

Decline in prevalence of human papillomavirus infection following vaccination among Australian Indigenous women

Skye McGregor, Dina Saulo, Julia Brotherton, Bette Liu, Samuel Phillips, S. Rachel Skinner, Michele Luey, Lisa Oliver, Mary Stewart, Sepehr N. Tabrizi, Suzanne Garland, John M. Kaldor

Vaccine 36 (2018) 4311–4316

Immunisation coverage annual report, 2014

Brynley P Hull, Alexandra J Hendry, Aditi Dey, Frank H Beard, Julia M Brotherton, Peter B McIntyre

Communicable Diseases Intelligence Volume 41 No 1 - March 2017

Opportunities to increase rates of human papillomavirus vaccination in the New South Wales school program through enhanced catch-up

Staples C, Butler M, Nguyen J, Durrheim DN, Cashman P, Brotherton JML

Sexual Health 2016. Published online 29 August 2016.

Immunisation coverage annual report, 2013

Hull BP, Dey A, Beard FH, Menzies RI, Brotherton JM and McIntyre PB

Commun Dis Intell Q Rep. 2016 Mar 31;40(1):E146-69

Primary Prevention of HPV through Vaccination: Update on Current Global Status

Brotherton JML, Zuber PLF and Bloem PJN

Curr Obst Gynecol Reports 2016. Published online 7 July 2016. doi: 10.1007/s13669-016-0165-z

Estimating human papillomavirus vaccination coverage among young women in Victoria and reasons for non-participation

Brotherton JML, Piers LS and Vaughan L

Sexual Health 2015

HPV vaccines: so much learnt, so many more lessons to come

Brotherton JML

Lancet Oncology 2016;17 (1):8-9. Published online 1 Dec 2015

IPVS Policy statement on safety of HPV vaccines

Garland SM, Stanley M, Brotherton J, Mosckiki A-B, Bhatla N, Kaufmann AM, Sankaranarayanan R and Palefsky J

Papillomavirus Research 2016;2:9-10

HPV vaccine impact in Australian women: ready for an HPV based screening program

Brotherton JML, Gertig DM, May CL, Chappell GA and Saville M

Med J Aust 2016; 204 (5): 184

Eurogin Roadmap 2015: How has HPV knowledge changed our practice: vaccines

Brotherton JML, Jit M, Gravitt P, Brisson M, Kreimer A, Pai S, Fakhry C, Monsonego J and Franceschi S

Int J Cancer 2016. Article first published online: 22 Mar 2016

Juvenile recurrent respiratory papillomatosis: 10 year audit and Australian prevalence estimates

Novakovic D, Cheng A, Baguley K, Walker P, Harrison H, Soma M, Malloy M and Brotherton JML

The Laryngoscope 2016. 2016 Apr 14. doi: 10.1002/lary.26005. [Epub ahead of print]

Monitoring the impact of HPV vaccine in males - considerations and challenges

Brotherton JML, Giuliano A, Markowitz L, Dunne E and Ogilvie G

Papillomavirus Research 2016;2:106-111

Measuring Human Papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia

Gertig DM, Brotherton JM and Saville AM

Sexual Health 2011: 8; 171-178

HPV Vaccination: Current Global Status

Brotherton JML and Bloem PJN

Curr Obstet Gynecol Rep 2015 DOI 10.1007/s13669-015-0136-9

Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: observational cohort of young women in Australia

Brotherton JML, Malloy M, Budd A, Saville M, Drennan K and Gertig DM

Papillomavirus Research. 2015

Current status of HPV vaccination

Brotherton JML and Ogilvie G

Current Opinion in Oncology 2015;27:399-404

Prophylactic HPV vaccines: lessons learned from 10 years’ experience

Brotherton JML

Future Virology 2015;10( 8):999-1009

Interim estimates of male human papillomavirus vaccination coverage in the school-based program in Australia

Brotherton JML, Batchelor MR, Bradley MO, Brown SA, Duncombe SM, Meijer D, Tracey LE, Watson M and Webby RJ

Comm Dis Intell Volume 39 Number 2 June 2015

Human Papillomavirus control. How are we going with vaccination coverage seven years in?

Brotherton J, Chappell G, Brosi J, Bicknell L, Winch K, Barbaro B, Saville M

Poster presentation Communicable Disease Control Conference - June 2015

Measuring HPV vaccination coverage in Australia: comparing two alternative population-based denominators

Barbaro B and Brotherton JML

Aust NZ J Public Health. 2015; Online; doi: 10.1111/1753-6405.12372

Could one dose of bivalent HPV vaccine prevent cancer?

Brotherton JML

Lancet Oncology. 2015. Published online 9 June 2015

Hepatitis B vaccines and HPV vaccines have been hailed as major public health achievements in preventing cancer - could a schistosomiasis vaccine be the third?

Hsieh MH, Brotherton JML and Siddiqui AA

PLoS Negl Trop Dis 9(5): e0003598

Human papillomavirus vaccination is changing the epidemiology of high-grade cervical lesions in Australia

Brotherton JML, Saville AM, May CL, Chappell GA and Gertig DM

Cancer Causes Control 2015; 26:953–954

Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis

Drolet M, Bénard É, Boily MC, Ali H, Baandrup L, Bauer H, Beddows S, Brisson J, Brotherton JM, Cummings T, Donovan B, Fairley CK, Flagg EW, Johnson AM, Kahn JA, Kavanagh K, Kjaer SK, Kliewer EV, Lemieux-Mellouki P, Markowitz L, Mboup A, Mesher D, Niccolai L, Oliphant J, Pollock KG, Soldan K, Sonnenberg P, Tabrizi SN, Tanton C and Brisson M

Lancet Infect Dis. 2015 May;15(5):565-80

Sexual Health

Special Issue: Human Papillomavirus Sexual Health Sept 2010, Vol 7, Issue 3

Two or three doses of HPV vaccine? [editorial]

Brotherton JML

BMJ 2015;350:g7778

The effect of making a ‘third dose assumption’ on human papillomavirus vaccination coverage estimates?

Brotherton JML and Winch K

Aust N Z J Public Health 2015;39:2:193-194

Australian Paediatric Surveillance Unit annual report, 2013

Marie Deverell, Yvonne A Zurynski, Elizabeth J Elliott, and all chief investigators of APSU surveillance studies

Commun Dis Intell 2014; 38(4):E343-7

Asking about human papillomavirus vaccination and the usefulness of registry validation: A study of young women recruited using Facebook

Gunasekarana B, Jayasinghe Y, Brotherton JML, Fenner Y, Moore EE, Wark JD, Fletcher A, Tabrizi SN and Garland SM

Vaccine 2014; 33:826-831

Assessing human papillomavirus genotype prevalence in young Australian women following the introduction of a national vaccination program

Osborne S, Tabrizi SN, Brotherton JML, et al

Vaccine 2015;33:201-208

What You Need to Know About: Human Papillomavirus Vaccination

Brotherton JML

British Journal of Hospital Medicine 2014;75(11):C165-C168

Immunisation coverage annual report, 2012

Hull BP, Dey A, Menzies RI, Brotherton JM and McIntyre PB

Commun Dis Intell. 2014;38(3):E208-E231

Early effect of the HPV vaccination program on cervical abnormalities in Victoria, Australia: an ecological study

Brotherton JML, Fridman M, May CL, Chappell G, Saville AM and Gertig DM

The Lancet 2011; 377:2085-2092

Offering HPV vaccination to women treated for high-grade cervical intraepithelial neoplasia: what you need to know [letter]

Brotherton JML and Wrede CD

ANZJOG 2014; 54: 393-4

Cervical screening rates for women vaccinated against human papillomavirus

Budd AC, Brotherton JML, Gertig DM, Chau T, Drennan K and Saville M

Med J Aust.2014;201:279-282

Assessing HPV vaccine coverage in Australia by geography and socioeconomic status: are we protecting those most at risk?

Barbaro B and Brotherton JML

Aust N Z J Public Health. 2014; Online; doi: 10.1111/1753-6405.12218

Assessment of herd immunity and cross-protection following a human papillomavirus vaccination programme: a repeat cross-sectional study

Tabrizi S*, Brotherton JML*, Kaldor JM, Skinner SR, Liu B, Bateson D, McNamee K, Garefalakis M, Phillips S, Cummins E , Malloy M and Garland SM. [* joint first authors]

Lancet Infect Dis.2014

Human papillomavirus vaccination: where are we now?

Brotherton JML

J Paed Child Health. 2014 doi:10.1111/jpc.12627

Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: a case-control study nested within a population-based screening program in Australia

Crowe E, Pandeya N, Brotherton JML, Dobson AJ, Kisely S, Lambert SB and Whiteman DC

BMJ 2014;348:g1458

Human papillomavirus vaccine introduction – the first five years

Markowitz LE, Tsu V, Deeks SL, Cubie H, Wang SA, Vicari AS and Brotherton JML

Vaccine 2012; 30 (S5), : F139-F148. ISSN 0264-410X, 10.1016/j.vaccine.2012.05.039

Barriers to better three-dose coverage with HPV vaccination in school based programs [letter]

Watson M, D’Onise K, Lynch J and Brotherton JML

Aust N Z J Public Health 2014;38(1):91-92

Human papillomavirus (HPV) vaccination coverage in young Australian women is higher than previously estimated: Independent estimates from a nationally representative mobile phone survey

Julia M.L. Brotherton, Bette Liu, Basil Donovan, John M. Kaldor and Marion Saville

Vaccine, 4 December 2013

HPV vaccine coverage in young women: results by Divisions of General Practice (2007-2009), and insights into under-notification

Laemmele-Ruff I, Barbaro B and Brotherton JML

Aust Fam Physician 2013;42(12):880-884

Human Papillomavirus vaccine coverage among female Australian adolescents: success of the school-based approach

Julia ML Brotherton, Sharron L Murray, Madeline A Hall, Lynne K Andrewartha, Carolyn A Banks, Dennis Meijer, Helen C Pitcher, Megan M Scully and Luda Molchanoff

MJA 199 (9) 4 November 2013: 614 - 617

Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study

Dorota M Gertig, Julia ML Brotherton, Alison C Budd, Kelly Drennan, Genevieve Chappell and A Marion Saville

BMC Medicine 2013, 11: 227

Utility of reports and routine correspondence from the National HPV Vaccination Program Register

Brotherton JML, Batchelor M and Winch K

Med J Aust 2013; 199 (7): 463

Safety of the quadrivalent human papillomavirus vaccine

Julia M L Brotherton

BMJ 2013;347:f5631

Safety of human papillomavirus vaccines: A review

Macartney KK, Chiu C, Georgousakis M, Brotherton J

Drug Safety 2013. DOI 10.1007/s40264-013-0039-5

Immunisation coverage annual report, 2011

Hull BP, Dey A, Menzies RI, Brotherton JM and McIntyre PB

Commun Dis Intell 2013;37(4):E291-E312

Fall in human papillomavirus prevalence following a national vaccination program

Tabrizi SN, Brotherton JML, Kaldor JM Skinner SR, Cummins E, Liu B, Bateson D, McNamee K, Garefalakis M, Garland SM

Journal of Infectious Diseases. 2012. 2012;206(11):1645-51

Human Papillomavirus vaccination and cervical cancer screening by socioeconomic status, Victoria

Barbaro B, Brotherton JML and Gertig DM

Med J Aust 2012 Vol 196 (7) p. 445

Expert Reviews - Primary prophylactic human Papillomavirus vaccination programs: future perspective on global impact

Brotherton JML and Gertig DM

Expert Rev. Anti. Infect. Ther. 2011: 9(8);627-639

Adolescent and young adult HPV vaccination in Australia: achievements and challenges

Garland SM, Skinner SR and Brotherton JML

Prev Med. 2011:53 Suppl 1:S29-35

Abnormal Pap tests after the HPV vaccine

Heley S and Brotherton JML

Australian Family Physician 2009: 38 (12); 977-979

Catching up with the catch-up: Interim HPV coverage data for Australian women aged 18-26 years from the National HPV Vaccination Program Register

Brotherton JML, Gertig DM, Chappell GA, Rowlands L and Saville M

Commun Dis Intell 2009: 33(4); 426-430